Harbour BioMed announces $225 million Series A to advance porustobart
Harbour BioMed says it has announced a $225 million Series A financing with partner Solstice Oncology to advance porustobart, a neoadjuvant immuno-oncology therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.